Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010 Aug 26;466(7310):1069-75. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. ALS—A Polyglutamine Disease? Mid-length Repeats Boost Risk
  2. Adding ALS to the Manifestations of VCP Mutations
  3. Corrupt Code: DNA Repeats Are Common Cause for ALS and FTD
  4. A Fork in the Road: Angiogenin Predisposes to ALS and Parkinson’s
  5. ALS-Linked TDP-43 Turns Amyloid in the Lab
  6. RNA Processors Turn Up in Another Motor Neuron Disease
  7. Yeast Models Say TDP-43 and FUS Are Not Cut From the Same Cloth
  8. Unusual ALS Case Highlights Variable Onset
  9. ALS-Linked Ataxin Repeats Stick It to TDP-43 in Stressed Cells
  10. RNA-Binding Protein Controls Ataxin-1 Expression
  11. Two For One? ASOs for Ataxin Allay ALS and SCA2 in Mice

Webinars

  1. Stress Granules and Neurodegenerative Disease—What’s the Scoop?

Therapeutics

  1. BIIB105